<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361541</url>
  </required_header>
  <id_info>
    <org_study_id>HCV-Epi</org_study_id>
    <nct_id>NCT02361541</nct_id>
  </id_info>
  <brief_title>Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia</brief_title>
  <acronym>HCV-Epi</acronym>
  <official_title>Determination of Hepatitis C Prevalence, Genetic Diversity and Treatment Eligibility in an HIV Patient Cohort in Phnom Penh, Cambodia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, Cambodia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Tropical Medicine, Belgium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C (HCV) is an important global public health problem, disproportionately affecting
      HIV positive populations. Asia and Africa account for most of the co-infection burden, but
      access to HCV screening and treatment is still very limited. It is expected though, with the
      recent therapeutic advances and increasing global advocacy efforts, that HCV treatment should
      become a feasible option in the near future.

      Sihanouk Hospital Center of HOPE (Phnom Penh, Cambodia) is catering for one of the largest
      HIV cohorts of the country, followed in an ambulatory settings. In this cohort, the
      prevalence of HCV co-infection will be determined, as well as HCV genotype diversity and the
      severity of liver disease. The researcher will also explore the performance of simple blood
      tests/panels as predictors of significant fibrosis and/or cirrhosis.

      Patients will attend two study-visits. All adult patients of the HIV patient cohort of SHCH
      will be proposed HCV testing during their next HIV follow-up consultation, following the
      latest algorithm of the Centre for Disease Control (CDC) (May 2013). Anamnesis and clinical
      examination will focus, additionally to routine practice, on presence of general and HCV
      liver-disease related features. Laboratory analyses will include basic HIV tests (CD4), and
      tests for liver function such as Hepatitis B surface antigen (HbsAg) .

      During the following routine HIV follow-up consultation, the results of HCV testing will be
      explained to the patient. If the patient is HCV negative, his/her study participation ends
      here. If currently infected with HCV, the clinician will repeat the HCV liver-disease
      (extra-hepatic &amp; hepatic) related anamnesis and clinical examination, and prescribe
      additional blood tests for the non-invasive liver fibrosis/cirrhosis blood panel tests, liver
      and kidney function. Patients will moreover be asked to undergo a liver ultrasound and liver
      stiffness measurements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C (HCV) is an important global public health problem, disproportionally affecting
      HIV positive populations. Asia and Africa account for most of the co-infection burden, but
      access to HCV screening and treatment is still very limited. The high cost and complexity of
      current diagnostic and treatment algorithms are major bottlenecks and the linked lack of
      accurate HCV prevalence estimates and treatment-need data do not allow for robust treatment
      advocacy and program planning. Cambodia is not an exception.

      It is expected though, with the recent therapeutic advances and increasing global advocacy
      efforts, that HCV treatment should become a feasible option in the near future. Sihanouk
      Hospital Center of HOPE (Phnom Penh, Cambodia) is catering for one of the largest HIV cohorts
      of the country, and it is planning to engage in HCV treatment from 2014 2015 onwards, with a
      double objective of direct patient benefit and catalyst role at national level, as in the
      past when starting its antiretroviral (ARV) program.

      Within this specific setting, the researchers plan to determine the prevalence of HCV
      co-infection, HCV genotype diversity and severity of liver disease in this HIV patient
      cohort, followed in an ambulatory setting. The researchers will also explore the performance
      of simple blood tests/panels as predictors of significant fibrosis and/or cirrhosis .

      The current HCV diagnostic procedures (and tools), as applied in this study, are too
      expensive and resource-demanding to allow for scalability in resource limited settings. Thus,
      the researchers plan to set up during this study a biobank with samples of a clinically well
      described HIV patient population. These samples should allow constituting a well-balanced
      panel for evaluation of future 'more scalable' HCV diagnostic tools.

      Patients will attend two study-visits. All adult patients of the HIV cohort will be proposed
      HCV testing during their next regular HIV follow-up consultation. HCV testing will follow the
      latest algorithm of the Centre for Disease Control (CDC) (May 2013). During this same
      consultation, anamnesis and clinical examination will focus, additionally to routine practice
      ,on presence of general and HCV liver-disease related features. Laboratory analyses will also
      include basic HIV (CD4), and tests for liver function such as Hepatitis B surface antigen
      (HbsAg).

      During the following routine HIV follow-up consultation (2-3 months later), the results of
      HCV testing will be explained to the patient. If the patient is HCV negative, his/her study
      participation ends here. If currently infected with Hepatitis C, the clinician will repeat
      the HCV liver-disease (extra-hepatic &amp; hepatic) related anamnesis and clinical examination
      and prescribe additional blood tests for the non-invasive liver fibrosis/cirrhosis blood
      panel tests, liver and kidney function. Patients will moreover be asked to undergo a liver
      ultrasound and liver stiffness measurements.

      The biobank will be set up with left over biological samples (whole blood plasma and serum)
      and comprehensive clinical information of all patients who give additional consent for this
      scope. Both biological samples and clinical information will be coded, to ensure
      confidentiality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprevalence of HCV infection</measure>
    <time_frame>Baseline</time_frame>
    <description>Seroprevalence of HCV infection in the HIV patient cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of current HCV infection</measure>
    <time_frame>Baseline</time_frame>
    <description>Proportion of currently infected with HCV among the HCV-IgG positive HIV patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HCV false-positives</measure>
    <time_frame>Baseline</time_frame>
    <description>Proportion of HCV biologically false-positives among HCV-IgG positive screening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV genotypes</measure>
    <time_frame>Baseline</time_frame>
    <description>Proportions of different HCV genotypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of liver disease in HCV patients</measure>
    <time_frame>Baseline</time_frame>
    <description>To determine the severity of liver disease by transient elastography in this coinfected cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV diagnostic accuracy</measure>
    <time_frame>Baseline</time_frame>
    <description>To compare the diagnostic accuracy of commonly available blood panel tests for fibrosis staging in this coinfected cohort, with liver stiffness measurement (considered as reference standard).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3045</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>HCV screening</arm_group_label>
    <description>All adult patients of an existing HIV cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HCV screening</intervention_name>
    <description>HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.</description>
    <arm_group_label>HCV screening</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Left over biological samples (whole blood plasma and serum)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients in a cohort of HIV-positive patients in Cambodia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt; or = 18 years old)

          -  Documented HIV positive

          -  In regular HIV care follow-up (min. 2 consultations in the last six months prior to
             the study)

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

        â€¢ HIV patients with currently taking Hepatitis C treatment or with a history of prior
        hepatitis C treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anja De Weggheleire, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Tropical Medicine, Antwerp, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>An Sokkab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sihanouk Hospital Center of HOPE (SHCH), Cambodia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sihanouk Hospital Center of HOPE (SHCH), Cambodia</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cambodia</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

